Chaanakya Capital is a San Francisco-based venture capital fund focused specifically on neurotechnology and medical technology at the earliest stages. The fund invests in pre-seed and seed companies developing neurostimulation, neuromodulation, neuroimaging, surgical tools, brain-computer interfaces, and related device-based approaches.

The fund is distinct in its explicit focus on non-pharmaceutical solutions for neurological and psychiatric conditions, including chronic pain, stroke, paralysis, and neurodegenerative disease. By concentrating on device and software-based neurohealth technologies rather than drugs, it occupies a relatively rare and highly specialized position within the market.

Its primary base is in the United States, although it has connections to internationally distributed teams. For neurotech founders, it is one of the clearest examples of a purpose-built early-stage investor with direct thematic alignment.